Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 1 - 50 av 114 resultater
Tid
Selskap
Tittel
Sektor
Kategori
07 Oct 2024
18:00 CEST
CELYAD ONCOLOGY
Celyad Oncology to Present at the 2024 SITC Annual Meeting
20103010 Biotechnology
Meetings / events
07 Oct 2024
18:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Présentera au Congrès Annuel SITC 2024
20103010 Biotechnology
Meetings / events
16 Sep 2024
18:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Announces Appointment of Matt Kane as Chief Executive Officer
20103010 Biotechnology
Corporate life
16 Sep 2024
18:00 CEST
CELYAD ONCOLOGY
Celyad Oncology annonce la nomination de Matt Kane au poste de CEO
20103010 Biotechnology
Corporate life
13 Sep 2024
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology publie ses résultats financiers pour le premier semestre 2024 ainsi que les récents évènements marquants de son activité
20103010 Biotechnology
Corporate life
13 Sep 2024
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Reports First Half Year 2024 Financial Results and Recent Business Highlights
20103010 Biotechnology
Corporate life
04 Apr 2024
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Reports Full Year 2023 Financial Results and Recent Business Highlights
20103010 Biotechnology
Corporate life
04 Apr 2024
07:00 CEST
CELYAD ONCOLOGY
Celyad Oncology publie ses résultats financiers pour l'année 2023 ainsi que les récents évènements marquants
20103010 Biotechnology
Corporate life
08 Feb 2024
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology annonce son intention de mettre fin à ses obligations de déclaration à la SEC
20103010 Biotechnology
Other subject
08 Feb 2024
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology Announces Intention to Terminate SEC Reporting Obligations
20103010 Biotechnology
Other subject
16 Jan 2024
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology Provides Fourth Quarter 2023 Business Update and 2024 Outlook
20103010 Biotechnology
Corporate life
16 Jan 2024
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology fait le point sur les activités du quatrième trimestre 2023 et présente ses perspectives pour 2024
20103010 Biotechnology
Corporate life
20 Dec 2023
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC
20103010 Biotechnology
Other subject
20 Dec 2023
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology SA : Publication d’une notification de transparence de Fortress Investment Group LLC
20103010 Biotechnology
Other subject
15 Dec 2023
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
20103010 Biotechnology
Other subject
15 Dec 2023
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology SA : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007)
20103010 Biotechnology
Other subject
04 Dec 2023
14:34 CET
CELYAD ONCOLOGY
Celyad Announces Management Change
20103010 Biotechnology
Corporate life
04 Dec 2023
14:34 CET
CELYAD ONCOLOGY
Celyad annonce un changement de direction
20103010 Biotechnology
Corporate life
30 Nov 2023
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology SA: Publication of a transparency notification received from Tolefi SA (Article 14 §1 of the Law of 2 May 2007)
20103010 Biotechnology
Legal
30 Nov 2023
22:01 CET
CELYAD ONCOLOGY
Celyad Oncology SA : Publication d’une notification de transparence reçue de Tolefi SA (Article 14 §1 de la loi du 2 mai 2007)
20103010 Biotechnology
Legal
21 Nov 2023
22:00 CET
CELYAD ONCOLOGY
Celyad Oncology SA : Publication d’une notification de transparence de Fortress Investment Group LLC
20103010 Biotechnology
Other subject
21 Nov 2023
22:00 CET
CELYAD ONCOLOGY
Celyad Oncology SA: Publication of a transparency notification received from Fortress Investment Group LLC
20103010 Biotechnology
Other subject
14 Nov 2023
22:00 CET
CELYAD ONCOLOGY
Celyad Oncology SA : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007)
20103010 Biotechnology
Other subject
14 Nov 2023
22:00 CET
CELYAD ONCOLOGY
Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
20103010 Biotechnology
Other subject
09 Nov 2023
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology publie ses résultats financiers pour le troisième trimestre de 2023 ainsi que ses récentes avancées
20103010 Biotechnology
Corporate life
09 Nov 2023
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology reports third quarter 2023 financial results and recent business highlights
20103010 Biotechnology
Corporate life
25 Sep 2023
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology Announces the Termination of Its American Depository Receipt Program
20103010 Biotechnology
Other subject
25 Sep 2023
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology annonce l’arrêt de son programme d’American Depositary Receipt
20103010 Biotechnology
Other subject
15 Sep 2023
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology SA : Publication d’une notification de transparence rectifiée de Fortress Investment Group LLC
20103010 Biotechnology
Other subject
15 Sep 2023
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology SA: Publication of a Rectified Transparency Notification Received From Fortress Investment Group LLC
20103010 Biotechnology
Other subject
12 Sep 2023
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology SA: Publication of a Transparency Notification Received from Tolefi SA
20103010 Biotechnology
Other subject
12 Sep 2023
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology SA : Publication d’une notification de transparence reçue de Tolefi SA
20103010 Biotechnology
Other subject
07 Sep 2023
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology SA : Notification de transparence de Fortress Investment Group LLC
20103010 Biotechnology
Other subject
07 Sep 2023
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC
20103010 Biotechnology
Other subject
05 Sep 2023
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology SA : Information relative au Nombre Total de Droits de Vote et d’Actions (Article 15 de la Loi du 2 Mai 2007)
20103010 Biotechnology
Other subject
05 Sep 2023
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology SA:Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
20103010 Biotechnology
Other subject
04 Sep 2023
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Présente ses Résultats Financiers pour le Premier Semestre de l’année 2023 et les Récents Evénements Marquants de son Activité
20103010 Biotechnology
Other subject
04 Sep 2023
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Reports First Half 2023 Financial Results and Recent Business Highlights
20103010 Biotechnology
Other subject
29 Aug 2023
18:00 CEST
CELYAD ONCOLOGY
Celyad Oncology Receives Approximately EUR 9.8m in Private Placement Commitments From Historical Shareholders
20103010 Biotechnology
Share introduction and issues
15 May 2023
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology Announces Receipt of Nasdaq Delisting Notice
20103010 Biotechnology
Other subject
15 May 2023
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology annonce la réception d’un avis de radiation du Nasdaq
20103010 Biotechnology
Other subject
05 May 2023
07:44 CEST
CELYAD ONCOLOGY
Celyad Oncology Announces Intent to Voluntarily Delist American Depository Shares From Nasdaq
20103010 Biotechnology
New
05 May 2023
07:44 CEST
CELYAD ONCOLOGY
Celyad Oncology annonce son intention de radier les American Depositary Shares de la Société du Nasdaq
20103010 Biotechnology
New
05 May 2023
07:42 CEST
CELYAD ONCOLOGY
Celyad Oncology Reports First Quarter 2023 Financial Results and Recent Business Highlights
20103010 Biotechnology
New
05 May 2023
07:42 CEST
CELYAD ONCOLOGY
Celyad Oncology publie ses résultats financiers pour le premier trimestre de 2023 ainsi que ses récentes avancées
20103010 Biotechnology
New
24 Apr 2023
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology Announces Receipt of Nasdaq Initial Notification on ADS Bid Price
20103010 Biotechnology
Legal
24 Apr 2023
22:01 CEST
CELYAD ONCOLOGY
Celyad Oncology annonce la réception d’une notification initiale du Nasdaq sur le prix de l’ADS
20103010 Biotechnology
Legal
04 Apr 2023
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology annonce la réception d’une notification du Nasdaq
20103010 Biotechnology
Other subject
04 Apr 2023
22:00 CEST
CELYAD ONCOLOGY
Celyad Oncology announces receipt of Nasdaq notice
20103010 Biotechnology
Other subject
24 Mar 2023
07:00 CET
CELYAD ONCOLOGY
Celyad Oncology nomme Georges Rawadi comme nouveau CEO
20103010 Biotechnology
Corporate life
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
1
2
3
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva